---
title: "XBIO.US (XBIO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/XBIO.US/news.md"
symbol: "XBIO.US"
name: "XBIO.US"
parent: "https://longbridge.com/en/quote/XBIO.US.md"
datetime: "2026-05-22T00:06:11.314Z"
locales:
  - [en](https://longbridge.com/en/quote/XBIO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/XBIO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/XBIO.US/news.md)
---

# XBIO.US (XBIO.US) — Related News

### [Xenetic Biosciences | 8-K: FY2026 Q1 Revenue: USD 800 K](https://longbridge.com/en/news/286257619.md)
*2026-05-13T12:07:12.000Z*
### [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform | XBIO Stock News](https://longbridge.com/en/news/286257227.md)
*2026-05-13T04:05:32.000Z*
> Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology 

### [Xenetic Biosciences | 10-Q: FY2026 Q1 Revenue: USD 806.92 K](https://longbridge.com/en/news/286154934.md)
*2026-05-12T20:40:18.000Z*
### [Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA](https://longbridge.com/en/news/281254166.md)
*2026-03-31T21:49:20.000Z*
> Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA

### [Xenetic Biosciences | 8-K: FY2025 Revenue: USD 3 M](https://longbridge.com/en/news/279039252.md)
*2026-03-13T12:02:10.000Z*
### [Xenetic Biosciences | 10-K: FY2025 Revenue: USD 2.976 M](https://longbridge.com/en/news/278943945.md)
*2026-03-12T21:03:34.000Z*
### [Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion](https://longbridge.com/en/news/278501704.md)
*2026-03-10T06:34:35.000Z*
> Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion

### [HENLIUS: Revised licensing agreement with Abbott Laboratories and KGBIO regarding Hansuzhuang®](https://longbridge.com/en/news/276707400.md)
*2026-02-24T09:00:57.000Z*
> On February 24, 2026, HENLIUS announced the revision and partial termination of the original licensing agreement with KG